SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001214659-22-004373
Filing Date
2022-03-25
Accepted
2022-03-25 17:51:18
Documents
1
Period of Report
2022-03-23

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT marketforms-55852.html 4  
1 PRIMARY DOCUMENT marketforms-55852.xml 4 4008
  Complete submission text file 0001214659-22-004373.txt   5395
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Issuer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences

Mailing Address C/O ALLOGENE THERAPEUTICS, INC. 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address
MOORE ALISON (Reporting) CIK: 0001754937 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38693 | Film No.: 22772697